Company Overview and News

4
Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy

2018-10-09 globenewswire
BASEL, Switzerland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD and AXO-AAV-OPMD, at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) being held in Lausanne, Switzerland from October 16th to 19th, 2018.
OXB OXBDF AXON

 
Oxford Biomedica PLC 2018 Q2 - Results - Earnings Call Slides

2018-09-13 seekingalpha
The following slide deck was published by Oxford Biomedica PLC in conjunction with their 2018 Q2 earnings call.
OXB OXBDF

9
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018

2018-09-13 globenewswire
Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2018.
IMDZ OXB LNSTY OXBDF AXON

5
Oxford BioMedica announces further capacity expansion with new facility

2018-09-13 globenewswire
Oxford, UK – 13 September 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a fifteen year lease on a new facility in Oxford that is close to its Windrush Court headquarters.
IMDZ OXB OXBDF

10
What Is Going On At Axovant Sciences?

2018-08-15 seekingalpha - 2
On February 12, 2018, Axovant Sciences (AXON) issued a press release noting changes to the management team and Board of Directors. Dr David Hung retired as CEO and Dr Pavan Cheruvu took his place, among other changes. Three and a half months of radio silence followed. What broke the silence? Another press release on May 29 noting additions to the management team and organizational restructuring. Things got interesting on June 6, when AXON reported it had licensed a gene therapy for Parkinson’s disease from Oxford BioMedica and of course made additional management changes.
ACAD OXB OXBDF AXON

 
Market report: Shares struggle as sterling falls to lowest level since September

2018-08-06 telegraph.co.uk
Mounting fears in the City of a no-deal Brexit dragged the pound down to an 11-month low as the FTSE 100 stagnated amid heightened trade war worries.
OXB OXBDF JLIF

5
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis

2018-08-06 globenewswire
Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis
IMDZ OXB OXBDF

8
Axovant Sciences Failed To Mention Critical Information

2018-07-15 seekingalpha - 3
On July 10th 2018 Axovant Sciences (AXON) announced a partnership with Benitec Biopharma (BNTC) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological disorders.
BLT OXB BNTC BNIKF OXBDF AXON BNTCW

7
Axovant, Benitec Gain on Licensing Deal for Gene Therapy

2018-07-10 zacks
Shares of Axovant Sciences (AXON - Free Report) gained after it announced a licensing agreement with Benitec Biopharma .
UNP BLT SLDB OXB BNTC BNIKF OXBDF AXON BNTCW

5
Axovant Licenses Benitec Gene Therapy Candidates for OPMD, Neurological Disorders

2018-07-09 genengnews
Benitec Biopharma could generate up to $655 million-plus in payments from licensing its preclinical gene therapy for oculopharyngeal muscular dystrophy (OPMD; pictured), and five additional Benitec gene therapy candidates for neurological disorders to to Axovant Sciences. [NIH]
BLT OXB BNTC BNIKF OXBDF ONCE BNTCW AXON

5
Axonant Showing Signs Of A Comeback As FDA Increases Scrutiny Of Compounding

2018-07-06 seekingalpha
The overall bioscience market traded with a mixed sentiment for the day. Many equities under our coverage continued to log in further profits for investors.
OXB ESPR IBB XBI OXBDF ONCE AXON

216
Voyager's Parkinson's Gene Therapy Is Likely To Fail

2018-07-01 seekingalpha - 2
Voyager needs to raises money; it will most likely be an equity offering before phase 1b and phase 1 posterior trajectory data is released.
VYGR OXB OXBDF SNY AXON

217
Rounds Report: Axovant Rallied While The FDA Approved Epidiolex

2018-06-27 seekingalpha - 1
We look for a horse with one chance in two of winning and which pays you three to one. - Charlie Munger
DOVA GWPH OXB IBB XBI OXBDF ONCE GWP AXON

213
A Deep Dive Into Axovant's Parkinson's Gene Therapy

2018-06-25 seekingalpha - 2
Axovant will be initiating a clinical trial with a second-generation gene therapy AXO-Lenti-PD later this year.
OXB OXBDF AXON

213
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

2018-06-19 zacks - 1
Shares of Solid Biosciences Inc. (SLDB - Free Report) surged 10.9% after the company announced that the FDA has lifted the clinical hold on its phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001.
SLDB OXB OXBDF NEE AXON

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: G6836F106